Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from NRXP

NRx Pharmaceuticals Q1 Earnings Call Highlights

NRx Pharmaceuticals (NASDAQ:NRXP) said it advanced several regulatory, manufacturing and clinical initiatives during the first quarter of 2026, including progress toward potential approval of its preservative-free ketamine product, KETAFREE, and preparations for an NDA filing for NRX-100. Founder,

HC Wainwright Finds 'Synergies In Treatment' For This Bipolar-Focused Stock

HC Wainwright Finds 'Synergies In Treatment' For This Bipolar-Focused Stock

HC Wainwright initiated coverage on NRx Pharmaceuticals Inc (NASDAQ:NRXP) with a Buying rating and a price target of $2. Earlier today, the FDA declined to issue an Emergency Use Authorization for NRx's Zyesami for a subgroup of patients who also received Gilead Sciences Inc's (NASDAQ:GILD) remdesivir in addition to Zyesami. The analyst is bullish on: Significant potential for NRX-101 for…

What's Next For NRx Pharma As FDA Denies Breakthrough Therapy Tag For COVID-19 Therapy

What's Next For NRx Pharma As FDA Denies Breakthrough Therapy Tag For COVID-19 Therapy

The FDA has denied NRx Pharmaceuticals Inc's (NASDAQ:NRXP) Breakthrough Therapy designation (BTD) request for Zyesami (aviptadil). The request for BTD was submitted based on a post-hoc subgroup analysis of patients who, in addition to aviptadil or placebo, were also treated with Gilead Sciences Inc's (NASDAQ: GILD) remdesivir and whose respiratory failure due to critical COVID-19 continued…

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Why NRX Pharmaceuticals Shares Are Trading Lower During Premarket On Thursday?

Based on the review of approximately 460 patients, Data Safety and Monitoring Board (DSMB) determined that the evaluation of NRx Pharmaceuticals Inc's (NASDAQ:NRXP) Zyesami (aviptadil) should cease due to futility. Aviptadil was the sole remaining investigational medicine in ACTIV-3b targeted at critical-ill COVID-19 patients. ACTIV-3b study evaluated Zyesami and Gilead Sciences Inc's (NASDAQ:GILD) Veklury (remdesivir)…

NRx Pharmaceuticals Again Requests For FDA Breakthrough Therapy Status For COVID-19 Therapy

NRx Pharmaceuticals Inc (NASDAQ:NRXP) has filed a new Breakthrough Therapy designation request with the FDA for Zyesami focused on a subgroup of critical COVID-19 patients. The subgroup includes patients who were also treated with Gilead Sciences Inc's (NASDAQ:GILD) Veklury (remdesivir) in addition to aviptadil or placebo. The request includes safety data on approximately 750 patients…

NRx Pharma Says I-SPY Study Of Inhaled Zyesami In Critical COVID-19 Stopped

Quantum Leap Healthcare Collaborative (QLHC) announced that the nebulized form of NRx Pharmaceuticals Inc's (NASDAQ: NRXP) Zyesami (Aviptadil) in the I-SPY COVID Trial of

NRX Pharmaceuticals Q4 2021 Earnings Conference Call On March 31, 2022 At 08:30 AM ET

NRX Pharmaceuticals (NASDAQ:NRXP) will host a conference call at 08:30 AM ET on March 31, 2022, to discuss Q4 2021 earnings results.

inkl

Read news from The Economist, FT, and more,
with one subscription

NRx Pharmaceuticals Raises $25M Via Equity To Support Its Pipeline Development

NRx Pharmaceuticals Raises $25M Via Equity To Support Its Pipeline Development

NRx Pharmaceuticals (NASDAQ: NRXP) has announced the private placement of 7.8 million shares priced at a premium to market under Nasdaq rule, for

NRx Pharma's COVID-19 Vaccine Candidate Show Potential Against Omicron Variant

NRx Pharma's COVID-19 Vaccine Candidate Show Potential Against Omicron Variant

NRx Pharmaceuticals (NASDAQ: NRXP) has received scientific evidence from the Israel Institute for Biological Research (IIBR) that the BriLife vaccine can

NRx Receives Initial Report of Patient Safety From 'Right To Try' Use Of Zyesami For COVID-19

NRx Receives Initial Report of Patient Safety From 'Right To Try' Use Of Zyesami For COVID-19

NRx Pharmaceuticals (NASDAQ: NRXP) has

NRx Pharma's Zyesami Access Expanded To COVID-19 Patients Who Exhausted All Approved Treatments

NRx Pharma's Zyesami Access Expanded To COVID-19 Patients Who Exhausted All Approved Treatments

NRx Pharmaceuticals (NASDAQ: NRXP) has announced enhancements to its

1

Organisations

Gilead Sciences Inc

National Institutes of Health

National Institute of Allergy and Infectious Diseases

NRx Pharmaceuticals

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

inkl

Read news from The Economist, FT, and more,
with one subscription

Places

405,389 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play